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Abstract: Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating disease 
presenting with extreme fatigue, post-exertional malaise, and other symptoms. In the absence of a 
diagnostic biomarker, ME/CFS is diagnosed clinically, although laboratory tests are routinely used 
to exclude alternative diagnoses. In this analytical cross-sectional study, we aimed to explore 
potential haematological and biochemical markers for ME/CFS, and disease severity. We reviewed 
laboratory test results from 272 people with ME/CFS and 136 healthy controls participating in the 
UK ME/CFS Biobank (UKMEB). After corrections for multiple comparisons, most results were 
within the normal range, but people with severe ME/CFS presented with lower median values (p < 
0.001) of serum creatine kinase (CK; median = 54 U/L), compared to healthy controls (HCs; median 
= 101.5 U/L) and non-severe ME/CFS (median = 84 U/L). The differences in CK concentrations 
persisted after adjusting for sex, age, body mass index, muscle mass, disease duration, and activity 
levels (odds ratio (OR) for being a severe case = 0.05 (95% confidence interval (CI) = 0.02–0.15) 
compared to controls, and OR = 0.16 (95% CI = 0.07–0.40), compared to mild cases). This is the first 
report that serum CK concentrations are markedly reduced in severe ME/CFS, and these results 
suggest that serum CK merits further investigation as a biomarker for severe ME/CFS. 
Keywords: myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), energy metabolism; 
potential biomarkers 
 
1. Introduction 
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is classified as a neurological 
disease [1], presenting with long-term fatigue resulting in substantial reductions in occupational, 
personal, social, and educational activities. Commonly-associated symptoms include impaired 
memory or concentration, muscle and multi-joint pain, new headaches, unrefreshing sleep, and post-
exertional malaise [2,3]. Many patients experience orthostatic intolerance and may complain of 
dizziness, spatial disorientation, sweating, palpitations, or fainting and generalised weakness [2–4]. 
Although dysregulation of the nervous, immune and endocrine systems, with impaired cellular 
energy metabolism and ion transport, has been suggested [2], the pathophysiology of ME/CFS is still 
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not fully understood, and there are no biological markers that are widely used for diagnosis, disease 
sub-grouping, or prognosis. 
ME/CFS is diagnosed using clinical criteria based on detailed clinical history and physical 
examination; laboratory tests are used to exclude other conditions that can present with fatigue and 
general ill health [2–5]. A major goal of clinical research in ME/CFS is to improve diagnosis and find 
clinical and laboratory-based tests that may be used as disease markers. In 2011 we launched the UK 
ME/CFS Biobank (UKMEB) as a resource to accelerate ME/CFS research [6]. A rigorous assessment, 
alongside comprehensive clinical phenotyping of UKMEB participants, is essential to ensure that 
ME/CFS diagnosis is accurate according to recognised clinical criteria. The analysis of these clinical 
data in relation to molecular markers further supports the better understanding of disease aetiology 
and pathophysiology. In this study we compared baseline laboratory tests results from UKMEB 
participants with ME/CFS, including mildly/moderately and severely affected (i.e., house-bound or 
bed-bound) individuals, and healthy controls, which were collected as part of the routine workup of 
participants. 
2. Materials and Methods 
This analytical cross-sectional study was carried out with a sub-cohort of the UKMEB consenting 
participants. Recruitment—including eligibility criteria, data and sample collection, and handling of 
biosamples for the UKMEB—are described in detail elsewhere [6]. Adult participants with ME/CFS 
previously diagnosed by general practitioners and/or ME/CFS specialists and healthy controls were 
recruited through the UK National Health Service (NHS). Inclusion criteria for participants with 
ME/CFS included compliance with the Centers for Disease Control and Prevention criteria (CDC, 
1994) or Canadian Consensus Criteria [2,3], which was ascertained by the clinical research team. 
Experienced research nurses assessed all participants, and blood was collected for immediate 
baseline clinical laboratory tests, as well as for research purposes and long-term storage. Blood 
collections took place at participating clinics or at the participants’ homes (for severely affected cases), 
and samples were transferred within 6 hours for processing and storage [7]. Data entry, sample 
transportation, preparation, processing, and storage of the samples followed standard operating 
procedures (SOPs) [6]. 
Baseline laboratory tests were used primarily to exclude participants with ME/CFS whose 
symptoms of chronic fatigue could be explained by other conditions. These tests comprised: full 
blood count, erythrocyte sedimentation rate (ESR), serum vitamin B12 and folate; biochemical tests 
including electrolytes, creatinine, urea, serum creatine kinase (CK), liver function tests, C-reactive 
protein, rheumatoid factor, thyroid function tests; tissue transglutaminase antibodies; and urine 
analysis for protein, glucose, and blood. CK isoenzymes, mainly produced in skeletal muscle (CK-
MM) and heart muscle (CK-MB), and aldolase were analysed in a sub-sample of 50 cases (25 severe 
and 25 non-severe cases) and 25 controls. According to the proximity of the collection site, blood 
samples were analysed by the haematology, clinical pathology, and immunology laboratories at the 
Norfolk and Norwich University Hospital or the Royal Free Hospital in London; standard NHS 
laboratory protocols were used for all tests [8]. The NHS laboratory staff was blinded to the status of 
study participants, i.e., if they were cases or controls. 
This study included a sample of 272 confirmed ME/CFS cases and 136 healthy controls. ME/CFS 
cases were further classified as mild/moderate (n = 216) or severe (n = 56). The definition of severity 
was made at recruitment based on whether the patient was mainly house-bound or bed-bound 
(severe) or was ambulatory (mild/moderate cases). We visually inspected the shape of the continuous 
variables’ distributions and, when departure from normality was observed, we used natural log 
transformation (CK, C-reactive protein (CRP), bilirubin, folate, vitamin B12) or square root 
transformation (ESR) to produce data that approximated a normal distribution for regression 
analysis. Figure A1 (Appendix A) shows the CK distribution before and after log transformation, by 
study group. We used log transformed results to carry out a power calculation of serum CK to detect 
mean differences of 0.34 (based on a standard deviation (SD) of 0.58 and means of 4.39 and 4.73 for 
cases and controls, respectively). We established that a sample size of at least 146 cases and 78 controls 
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would be adequate to detect mean differences with a power or 95% and a type I error of 1%. The 
number of missing values was lower than 5% across all the variables, apart from one blood test 
(erythrocyte sedimentation rate) whose proportion of missing results was similar among the groups 
(16.5% to 17.6%); thus, we opted to maintain the variable in the analyses. Univariate analyses were 
performed using chi-squared tests for comparison of proportions and analysis of variance (ANOVA) 
for comparison of means of normally distributed continuous variables. For significant departures 
from normality, Wilcoxon rank sum or Kruskal–Wallis tests [9] were used to compare medians 
between two or more unmatched study groups respectively. 
For putatively interesting results from the univariate analyses (Wilcoxon rank-sum test p < 0.01), 
logistic regression analyses [9] were used, and included the covariates: age-group at the time of 
recruitment, sex, body mass index (as ascertained during physical examination, in kg/m2), disease 
duration (in months, for comparisons between cases only), muscle mass index percentage of total 
body weight (using a Tanita BC-418 MA body composition analyser), and recent activity levels. 
Activity levels were estimated from answers to specific questions on the bespoke participant 
questionnaire: participants were asked to put their perceived activity levels over the 7 days preceding 
the blood draw into one of five categories, ranging from “not active at all” to “very active”. For some 
analyses, the two categories of activity at the extremes were merged, and the variable used had three 
resulting categories. The linearity assumption of covariates within the logistic regression models was 
assessed using generalised additive models (the “mgcv” package in R) [10]. The linearity assumption 
was satisfied in all models and so activity level was treated as an ordinal categorical variable when 
adjusting in multivariate analyses. To minimise potential type I errors, due to multiple testing, a 
Bonferroni-based threshold of p <0.001 was conservatively established (i.e., we divided the 
statistically significant level of 0.05 by the 29 number of individual laboratory tests that were 
compared, totalling 0.0017). We also used receiver operating characteristic (ROC) curves to assess 
whether the laboratory test results were able to discriminate people with ME/CFS (PWME) from 
healthy controls, or people with mild/moderate ME/CFS from those with severe symptoms. This type 
of analysis produces a curve chart that shows sensitivity vs. specificity, and the resulting area under 
the curve (AUC) represents how well a laboratory test can distinguish between two groups: diseased 
versus non-diseased, or having mild/moderate ME/CFS versus severe symptoms [9]. The ROC curves 
were calculated using the “pROC” package in R. All analyses were performed using Stata® version 
15.1 or the R-statistical platform [10]. 
Ethics approval and consent to participate: Ethical approval was granted by the LSHTM Ethics 
Committee 16 January 2012 (Ref.6123) and the National Research Ethics Service (NRES) London—
Bloomsbury Research Ethics Committee 22 December 2011 (REC ref.11/10/1760, IRAS ID: 77765). All 
biobank participants provided written consent for questionnaire, clinical measurement, and 
laboratory test data, and samples to be made available for ethically-approved research, after receiving 
an extensive information sheet and consent form, which includes an option to withdraw from the 
study at any time. 
Availability of data and material: The datasets used and/or analysed during the current study 
are available upon request, from the UK ME/CFS Biobank UKMEB Steering Committee, who 
considers requests from data and/or biosamples, as per UKMEB protocols 
(https://cureme.lshtm.ac.uk/researchers/protocols-application-documents/). 
3. Results 
Table 1 shows the distribution of baseline variables by study group. The proportion of women 
was higher among cases, who were on average less active and had lower body muscle mass. Mild 
cases had the highest body mass index (BMI) compared to severe cases (lowest) and healthy controls 
(Table 1). 
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Table 1. Baseline characteristics of study participants. 
Characteristic 
Healthy Controls  
(n = 136)  
n (%) 
Mild/Moderate 
ME/CFS Cases 
(n = 216) n (%) 
Severe 
ME/CFS Cases 
(n = 56) n (%) 
p-Value 
(hc/mm/sa) 
p-Value 
(hc/me) 
Female 84 (61.8) 166 (76.9) 43 (76.8) 0.006 a 0.001 a 
Male 52 (38.2) 50 (23.1) 13 (23.2)   
Age (years)    0.900 a 0.900 a 
18–29 23 (16.9) 34 (15.7) 10 (17.8)   
30–39 34 (25) 48 (22.3) 13 (23.2)   
40–49 35 (25.7) 64 (29.6) 12 (21.5)   
50–60 44 (32.4) 70 (32.4) 21 (37.5)   
Level of activity *      
Very active 33 (25.2) 1 (0.6) 2(3.5) <0.0001 a <0.0001 a 
Rather active 59 (45) 25 (12.3) 3 (5.3)   
Neither active nor 
inactive 
22 (16.8) 49 (24.1) 3 (5.3)   
Rather inactive 16 (12.3) 91 (44.8) 15 (26.8)   
Not at all active 1 (0.7) 37 (18.2) 33 (59.1)   
Body mass index 
(mean) * 
25.96 27.17 23.73 0.002 b 0.360 b 
Body muscle (%) * 49.5 46.3 45.7 0.003 b 0.001 b 
a χ2test; b ANOVA; p-values compare healthy controls with mild–moderate cases and with severe 
cases (penultimate column), and with all myalgic encephalomyelitis (ME) or chronic fatigue 
syndrome (CFS) cases (last column). * The number of participants with missing data on level of 
activity was 18 (5 healthy controls, 13 mild/moderate ME/CFS cases); 4 severely-affected ME/CFS 
cases were missing body mass index (BMI) data; and 5 severely-affected ME/CFS cases were missing 
data on body muscle. ME/CFS = Myalgic Encephalomyelitis/Chronic Fatigue Syndrome; hc = healthy 
controls, mm: ME/CFS mild/moderately affected; sa = ME/CFS severely affected; me = ME/CFS cases. 
Nineteen biochemical and 10 haematological tests were performed across the participants 
(Tables 2 and 3). As expected, there were correlations between many of the test results (Spearman’s 
Correlation: median 0.09; range 0.00–0.94), including between: (i) creatinine and urea, and of both 
with CK (range: 0.35–0.40); (ii) CK and aspartate aminotransferase (AST) (0.40); (iii) albumin and free 
T4, total protein and globulin (0.35–0.62); (iv) C-Reactive Protein (CRP) and Erythrocyte 
Sedimentation Rate (ESR) (0.47); (v) monocytes with white blood cells, lymphocytes and neutrophils 
(0.42–0.91) (Supplementary Figures S1 and S2). In Appendix B (Table A1) we present the reference 
ranges for the laboratory tests, analysed in this paper. The distributions of the analytes were 
compared between cases and controls (Table 2), and between severe and non-severe ME/CFS cases 
(Table 3). ESR, platelets, and CRP were raised in PWME, while CK and urea were reduced (Table 2; 
Wilcoxon rank sum p < 0.01). Compared with mild cases, those with severe disease had raised 
albumin, free T4 and serum folate, and lower CK, CRP, potassium, creatinine, and bilirubin (Table 
3; Wilcoxon rank sum p < 0.01). 
The reduced CK values were mainly due to low values of CK-MM isoenzyme, for which the 
mean was 44 U/L (interquartile range (IQR) = 24–86) in severe cases, compared to 73 (IQR = 37–94) in 
the mild/moderately affected and 90 (IQR = 41–238) in healthy controls (p = 0.03). CK-MB and aldolase 
values were also lowest in severely affected cases (Kruskal–Wallis p-values of 0.27 and 0.09, 
respectively). The ratio of CK-MB/CK-total was highest in the severe 0.26 (IQR = 0.18–0.39), compared 
to 0.20 (IQR = 0.10–0.32) in non-severe cases and 0.14 (IQR = 0.09–0.25) in healthy controls (p = 0.03), 
confirming the main contribution of reduced CK-MM values to the low concentration of total CK in 
cases, and particularly the severely affected (see also Tables 2 and 3). Total CK correlated very 
strongly with CK-MM (r = 0.99) in all study groups, but weaker correlations were found between 
total (CK) and CK-MB (from r = 0.22 in the severely affected, r = 0.32 in milder cases, and r = 0.63 in 
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controls). This further demonstrates CK-MM as the main driver of reduced total CK concentrations 
in ME/CFS. 
Table 2. Comparison of baseline laboratory haematological and biochemical test results from ME/CFS cases 
and healthy controls. 
Assay All Cases (n = 272) 
Median 
IQR Healthy Controls 
(n = 136) Median 
IQR Wilcoxon 
p a 
WBC (109/L) 6.1 (5.2,7.3) 5.9 (5.1,6.8) 0.268 
Platelets (109/L) 262 (226,310) 247 (206,282) <0.001 
Haemoglobin (g/L) 137 (129,148) 139 (130,149) 0.433 
Haematocrit 0.412 (0.391,0.438) 0.418 (0.395,0.446) 0.165 
Neutrophils (109/L) 3.47 (2.72,4.28) 3.28 (2.56,4.31) 0.374 
Lymphocytes 
(109/L) 
1.88 (1.61,2.30) 1.815 (1.525,2.140) 0.146 
Monocytes (109/L) 0.43 (0.34,0.55) 0.43 (0.35,0.55) 0.869 
Eosinophils (109/L) 0.135 (0.80,0.24) 0.14 (0.09,0.22) 0.701 
Basophils (109/L) 0.03 (0.02,0.05) 0.03 (0.02,0.04) 0.923 
ESR (mm/h) 7 (4,12) 5 (2,8) <0.001 
Sodium (mmol/L) 140 (139,142) 140 (139,142) 0.336 
Potassium (mmol/L) 4.2 (4.0,4.4) 4.2 (4.0,4.4) 0.680 
Urea (mmol/L) 4.3 (3.5,5.1) 4.8 (3.9,5.7) <0.001 
Creatinine (umol/L) 74 (67,85) 77 (66,88) 0.539 
Adj. calcium 
(mmol/L) 
2.36 (2.31,2.42) 2.37 (2.32,2.41) 0.900 
Inorg. phosphate 
(mmol/L) 
1.03 (0.90,1.16) 1.05 (0.93,1.14) 0.452 
Total bilirubin 
(umol/L) 
9 (7,11) 9 (7,13) 0.087 
Albumin (g/L) 44 (41,47) 44 (41,47) 0.531 
Globulins (g/L) 31 (29,32) 30 (28,32) 0.363 
ALP (U/L) 67 (56,80) 63.5 (52,75) 0.055 
AST (U/L) 20 (16,23) 20 (18,24) 0.247 
Total protein(g/L) 73 (70,76) 72 (68,75) 0.023 
CK (U/L) 80 (56,107) 101.5 (76,152) <0.001 
CK-MM (U/L) * 55 (28,100) 90.0 (41,238) 0.030 
CK-MB (U/L) * 17 (14,22) 17 (14-23) 0.780 
Aldolase * 3.8 (2.8,4.6) 4.0 (2.8,4.6) 0.620 
CRP (mg/L) 2 (1,4) 1 (1,3) 0.007 
Free T3 (pmol/L) 4.5 (4.1,4.9) 4.6 (4.2,5.1) 0.238 
Free T4 (pmol/L) 14 (13,16) 14 (3,16) 0.242 
TSH (mU/L) 1.6 (1.2,2.3) 1.62 (1.15,2.40) 0.637 
Serum vitamin B12 
(pg/mL) 
388 (310,539) 379 (309,462) 0.164 
Serum folate (ng/m) 8.6 (5.6,12.6) 9.0 (6.6,12.2) 0.313 
a Wilcoxon rank sum test; * For CK isoenzymes CK-MM and CK-MB and aldolase, n = 50 cases and 25 
controls. WBC = white blood cells; ESR = erythrocyte sedimentation rate; Adj. calcium = adjusted 
calcium; Inorg. phosphate = inorganic phosphate; ALP = alkaline phosphatase; AST = aspartate 
aminotransferase; CK = creatine kinase; CK-MM = CK produced in skeletal muscle; CK-MB = CK 
produced in heart muscle; CRP = C-reactive protein; TSH = thyroid stimulating hormone; IQR = 
interquartile range. In bold are variables (p < 0.001) carried forward for regression analysis.   
Diagnostics 2019, 9, 41 6 of 16 
 
Table 3. Comparison of baseline laboratory haematological and biochemical test results from severe and 
mild/moderate ME/CFS cases. 
Assay Severe cases  (n = 56) Median IQR 
Mild cases  
(n = 216) 
Median 
IQR Wilcoxon  
p a 
WBC (109/L)  5.85 (5.05,7.54) 6.11 (5.2,7.1) 0.744 
Platelets (109/L) 254.5 (221,305) 266 (229,310) 0.585 
Haemoglobin (g/L) 134 (126,144) 137.5 (130,149) 0.038 
Haematocrit 0.405 (0.388,0.428) 0.413 (0.391,0.440) 0.156 
Neutrophils (109/L)  3.44 (2.89,4.20) 3.485 (2.68,4.32) 0.856 
Lymphocytes (109/L) 1.785 (1.59,2.05) 1.915 (1.62,2.32) 0.061 
Monocytes (109/L)  0.46 (0.36,0.59) 0.425 (0.34,0.54) 0.078 
Eosinophils (109/L)  0.165 (0.075,0.265) 0.13 (0.08,0.23) 0.366 
Basophils (109/L)  0.03 (0.02,0.05) 0.03 (0.02,0.04) 0.697 
ESR (mm/h) 5 (2,10) 7 (5,12) 0.057 
Sodium (mmol/L) 141 (140,142) 140 (139,141) 0.015 
Potassium (mmol/L) 4 (3.8,4.3) 4.2 (4.0,4.4) 0.003 
Urea (mmol/L) 4.15 (3.4,5.1) 4.3 (3.5,5.2) 0.317 
Creatinine (µmol/L) 65 (59,74) 78 (68,86) <0.001 
Adj. calcium 
(mmol/L) 
2.35 (2.29,2.41) 2.37 (2.31,2.42) 0.048 
Inorg, phosphate 
(mmol/L)  
1.03 (0.93,1.16) 1.03 (0.89,1.16) 0.439 
Total bilirubin 
(µmol/L) 7 (5,9) 9 (7,12) <0.001 
Albumin (g/L) 46 (44,49) 43 (40,46) <0.001 
Globulins (g/L)  29 (29,29) 31 (29,33) 0.542 
ALP (U/L)  64 (54,80) 67 (56,81) 0.388 
AST (U/L)  19 (16,22) 20.5 (16.5,24.0) 0.438 
Total protein(g/L)  68 (68,68) 73 (70,76) 0.148 
CK (U/L)  54 (45,78) 84 (63,113) <0.001 
CK-MM (U/L) * 44 (24,86) 73 (37,194 0.030 
CK-MB (U/L) * 16 (13,20) 19 (17,22) 0.080 
Aldolase * 3.6 (2.5,4.0) 4.0 (2.8,4.6) 0.040 
CRP (mg/L) 1 (1,5) 2 (2,6) <0.001 
Free T3 (pmol/L)  4.4 (4.1,4.7) 4.6 (4.2,4.9) 0.073 
Free T4 (pmol/L) 16.1 (14.2,18.0) 14.0 (13.0,15.3) <0.001 
TSH (mU/L)  1.59 (1.14,2.28) 1.61 (1.16,2.40) 0.795 
Serum vitamin B12 
(pg/mL) 
449 (333,659) 382 (305,532) 0.038 
Serum folate (ng/m) 9.8 (8.0,14.7) 7.6 (5.0,12.6) 0.002 
a Wilcoxon rank sum test; * For CK isoenzymes CK-MM and CK-MB and aldolase, 25 cases in each 
group. WBC = white blood cells; ESR = erythrocyte sedimentation rate; Adj. calcium = adjusted 
calcium; Inorg, phosphate = inorganic phosphate; ALP = alkaline phosphatase; AST = aspartate 
aminotransferase; CK = creatine kinase; CK-MM = CK produced in skeletal muscle; CK-MB = CK 
produced in heart muscle; CRP = C-reactive protein, TSH = thyroid stimulating hormone, IQR = 
interquartile range. In bold are variables (p < 0.01) carried forward for regression analysis. 
Table 4 shows results of the multivariate logistic regression, from which (ln) CK levels were 
shown to be inversely associated with the risk of being a ME/CFS case compared with being a healthy 
control (odds ratio (OR) 0.36; p < 0.001). The same analysis focusing on severe cases (vs. controls) 
revealed elevated risks associated with lower (ln) bilirubin (OR 0.23; p < 0.001) and lower (ln) CK (OR 
0.05; p < 0.001), as well as with higher albumin (OR 1.20; p < 0.001) and T4 (OR 1.42; p < 0.001). 
Similarly, lower levels of creatinine (OR 0.91; p < 0.001), (ln) bilirubin (OR 0.15; p < 0.001) and (ln) CK 
(OR 0.16; p < 0.001) were associated with increased risk of severe compared to mild ME/CFS. 
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Consistent with the above, increased albumin levels were associated with greater risk of being a 
severe compared to a mild case (OR 1.25; p < 0.001). 
Table 4. Laboratory test results in ME/CFS cases and healthy controls (adjusted analysis ***). 
 Assay Odds Ratio (95% CI) p-Value 
ME/CFS cases vs. 
healthy controls 
Platelets 1.01 (1.00–1.01) 0.007 
Urea 0.78 (0.65–0.94) 0.008 
CK * 0.36 (0.23–0.57) <0.001 
CRP * 1.37 (0.99–1.90) 0.059 
ERS ** 1.33 (1.04–1.71) 0.023 
Severe ME/CFS cases 
vs. healthy controls 
Urea 0.71 (0.53–0.96) 0.027 
Creatinine 0.95 (0.91–0.98) 0.001 
Bilirubin * 0.23 (0.10–0.52) <0.001 
Albumin 1.20 (1.08–1.33) <0.001 
CK * 0.05 (0.02–0.15) <0.001 
T4 1.42 (1.21–1.66) <0.001 
Vit. B12 * 4.12 (1.64–10.36) 0.0026 
Severe ME/CFS cases 
vs. mild/ moderate 
ME/CFS cases **** 
Potassium 0.38 (0.13–1.13) 0.082 
Creatinine 0.91 (0.87–0.94) <0.001 
Bilirubin * 0.15 (0.06–0.36) <0.001 
Albumin 1.25 (1.13–1.38) <0.001 
CK * 0.16 (0.07–0.40) <0.001 
CRP * 0.56 (0.32–0.97) 0.040 
T4 1.26 (1.09–1.45) 0.0014 
Folate * 1.83 (0.98–3.40) 0.058 
* ln transformed; ** Square-root transformed; *** Adjusted for sex, age-group, BMI, and muscle mass, 
current physical activity level; **** Further adjusted for disease duration; ME/CFS = Myalgic 
Encephalomyelitis/Chronic Fatigue Syndrome; ESR = erythrocyte sedimentation rate, CK = creatine 
kinase, CRP = C-reactive protein. Bolded text signifies p < 0.001. 
Across the analyses, differences in CK were the most consistent; there were marked differences 
between cases and healthy controls, with severe cases having much lower levels than mild/moderate 
cases or healthy controls (Figure 1a). By refitting the different outcome models either with urea, 
creatinine, bilirubin, albumin, T4 and CK, or with CK alone, we could estimate the value of CK as a 
potential marker for ME/CFS (Figure 1b). The ROC curve analysis for routine serum CK had a limited 
role in distinguishing ME/CFS cases from healthy controls (AUC = 67%) but had a potential role in 
distinguishing severely affected participants with ME/CFS from those with mild/moderate ME/CFS 
(AUC = 75%) and from healthy controls (AUC = 84%) (Figure 1b). A full model adding CK, bilirubin, 
albumin, T4, creatinine, and CRP, improved predictions, particularly when severe cases were 
compared to non-severe cases and healthy controls (AUC = 91%; improvement over CK alone p << 
0.001), and a reduced model of CK, bilirubin, albumin and T4 (based on Table 4) had similar 
performance (AUC = 90%). 
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Figure 1. (a) Levels of CK and disease outcome. CK was measured in healthy controls n = 136, 
mild/moderate ME/CFS cases n = 216, and severe ME/CFS cases n = 56. Intercept 5.07411 (se 0.07907, 
p < 0.001); slope-0.31797 (se 0.04120, p = 0.001). (b) ROC curves showing the predictability of a “full” 
model (including urea, creatinine, bilirubin, albumin, CK, T4; dashed lined) vs CK alone (solid line); 
areas under the curve (AUC) are presented in the legend. CK = creatine kinase; ME/CFS = Myalgic 
Encephalomyelitis/Chronic Fatigue Syndrome; ROC = Receiver Operating Curves. 
We found a cut-off value of 51 U/L for serum CK to have high sensitivity for both ME/CFS groups 
of severity compared to controls (sensitivity = 96%), and for severe ME/CFS cases compared to 
mild/moderate cases (sensitivity = 88.7%). However, these have low specificity (<50%). 
Considering the strong association between activity levels and participant category—either case 
or control (p < 0.0001)—we explored further the association between ln CK values and participant 
category in three different strata of activity levels, i.e., “not at all active or rather inactive”, “neither 
active nor inactive”, and “rather active or very active”. The results presented in Table 5, show clear 
trends towards lower CK values in cases, particularly as those severely-affected are compared with 
healthy controls. The highest significant levels are seen in those who declared they have been inactive 
(p < 0.001). 
Table 5. Median total CK (IQR) according to reported activity levels *. 
 Inactive (n = 190) Average (n = 72) Active (n = 121) 
Healthy controls (n = 129) 76(70,157) 98(66,152) 110(84,153) 
Mild/moderate ME/CFS cases (n = 199) 82(61,110) 92 (68,143) 85(73,108) 
Severe ME/CFS cases (n = 55) 52(45,77) 46 (44,78) 60(46,91) 
p-value ** <0.001 0.200 0.020 
* Association between activity levels and case category (chi-squared test) p < 0.0001; ** p-value for 
Kruskal–Wallis statistics comparing CK in healthy controls, mild-moderate, and severe cases within 
each activity level group. 
4. Discussion 
Routine laboratory tests are usually reported as normal in PWME, when they are used to exclude 
other illnesses causing chronic fatigue. Among the routine laboratory tests for ME/CFS is serum CK, 
with studies typically reporting CK results within normal ranges if, indeed, they are reported [11,12]. 
We found that PWME had lower CK levels than healthy controls, and that CK was significantly lower 
in people with severe ME/CFS compared to those who were mild/moderately affected. The 
associations persisted after adjusting for sex, age-group, BMI, muscle mass, or recent physical activity 
levels (all of which potentially affect CK concentrations in serum [13,14]), as well as disease duration 
where appropriate (i.e., when comparing cases of differing severity levels). Creatinine and bilirubin 
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were also found to be significantly lower in severely-affected patients compared to mild/moderate 
cases, while albumin was higher in severe cases. There was a trend towards higher levels of CRP and 
ESR in ME/CFS, and particularly in those with mild/moderate disease. CK levels were found to be 
good predictors of severe ME/CFS cases as compared to those who were less severely-affected or 
healthy controls; this was enhanced by the inclusion of other laboratory tests results in the model. 
4.1. The Physiological and Clinical Importance of CK 
CK is a key enzyme involved in energy production and homeostasis processes, particularly in 
tissues with highly dynamic and fluctuating energy demands which must be quickly satisfied, such 
as the brain, skeletal muscle, and heart [15]. It is also present in many other cells, such as immune 
and epithelial cells, where it also plays a crucial role in energy production [16,17]. 
Cellular energy is mainly generated from the breakdown of the high-energy molecule, 
adenosine triphosphate (ATP). Although the complex mechanisms of cellular energy balance are not 
fully understood, there is evidence that muscle cells depend on several processes to increase energy 
availability and to avoid complete energy depletion by drawing on stores of ATP. CK plays a crucial 
role in these processes: firstly, by establishing an efficient cytosolic storage of high-energy phosphates 
for rapid ATP replenishment [13], it catalyses the relocation of γ-phosphate from ATP to creatine to 
generate phosphocreatine and adenosine diphosphate (ADP), in a reversible process [18]; and 
secondly, it is involved in the transfer of high-energy phosphate from the mitochondria to the muscle 
cell cytoplasm, where it is used during muscle contraction [19]. Thus, measures of CK in serum may 
indicate the availability of cellular energy [13]. 
CK serum concentrations are widely used to diagnose and monitor a range of muscle diseases 
when high levels are clinically relevant. CK levels are known to increase with muscle injury and 
inflammation [13], and may also be high in hypothyroid myopathy and secondary to treatment with 
statins [14]; increased levels of serum CK can be seen in trained athletes and in individuals after 
extreme exercise [20]. There are three types of CK, called isoenzymes: CK-MM (found in muscle and 
raised in many muscle diseases), CK-MB (present in heart muscle in particular), and CK-BB (found 
mostly in the brain but usually undetectable in peripheral blood) [13]. CK-MB used to be widely used 
in the diagnosis of ischaemic heart disease, though it has now been superseded by other disease 
markers [21]. 
Low serum CK concentrations have been reported less frequently, but they may be of clinical 
significance in some rheumatological [22,23] and connective tissue diseases [24]. The causes and 
significance of these findings are unclear, but it has been suggested that serum CK may be inversely 
related to inflammatory processes [24,25], and low CK levels have been associated with muscle 
weakness, independently of muscle atrophy [23]. A study on patients with severe renal failure 
reported a significant association between lower serum CK and an increased risk of death, and 
suggested that their serological findings might be explained by the patients’ wasted muscle mass and 
poor nutritional status [26], but there was no subsequent suggestion of using serum CK for diagnosis 
or management of these conditions. In studies on Huntington’s disease, a severe degenerative 
neurological disease [27], it has been suggested that reduced brain energy may result from the 
reduced activity of the CK system, and that loss of CK-BB may be an important unrecognized 
biomarker of this disease. 
The low concentrationsof serum CK found in people with ME/CFS suggests an abnormality in 
energy metabolism, which have been reported by distinct authors (e.g., references [28–32]) and could 
explain the intolerance to exertion commonly reported by patients, and consequent reduction in 
activity levels [2]. An alternative or additional explanation is that the lower serum CK resulted, at 
least partially, from physical inactivity. Nevertheless, the persistent significant association between 
lower serum CK and disease severity in the multivariate model that controls for activity suggests that 
these results cannot be fully explained by reduced physical activity, but that there are other factors 
involved. To explore further a potential confounding role of activity levels, we compared median 
serum values of CK in different strata of activity category. The values were reduced in severely 
affected cases in all strata Nevertheless, the potential for residual confounding is still present, and 
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differential misclassification on activity levels, with over-estimation of activity in severe ME/CFS 
cases, remains a possible (and at least partial) explanation, for the difference in the levels of CK 
observed. However, with the increasing number of reports on energy metabolism abnormalities in 
people with ME/CFS, further exploration of this association is warranted. 
In addition to intolerance to physical exercise, patients with ME/CFS usually also report mental 
fatigue and “brain fog”, as well as subjective muscle weakness [2,4,33]. Considering the importance 
of CK in both muscle and brain metabolism, the low concentrations of this enzyme could, at least 
partially, explain those symptoms. 
Some researchers have previously reported intriguing findings on serum CK in PWME. For 
example, two studies with 30 and 33 individuals, compared the CK serum concentration of ME/CFS 
patients (diagnosed by the CDC-1994 criteria [3]) with those of healthy controls before and after 
exercise, in order to evaluate physical capacity [34,35]. The mean CK in PWME was lower, though 
not significantly, than in controls, and did not increase with exertion in those with ME/CFS (as seen 
in healthy individuals). The results suggests that lack of acute physical effort was not the main factor 
determining CK levels in PWME [34,35]. Another study on PWME found higher serum CK in 
participants with enterovirus-specific RNA detected in muscle by biopsy, than in those with no 
evidence of enteroviral infections. That study suggested that a sub-group of PWME might have 
muscle damage secondary to enterovirus infection, but unfortunately, the authors did not specify the 
concentrations of CK in the group of patients with lower values [36]. 
Other studies have considered possible mitochondrial function impairment in ME/CFS, which 
reinforces the plausibility of metabolic dysfunction in the energy system (e.g., references [28–30]) as 
our findings indicate. 
4.2. Other Study Findings 
Creatinine levels were found to be significantly lower in severe ME/CFS. Creatine phosphate 
(CP) is converted to creatinine in muscle and creatinine is excreted in urine [13], so low CP resulting 
from poor conversion of creatine to CP by CK could explain the low levels of creatinine found in 
severe ME/CFS. Low urine concentration of creatinine have also been reported [37]. 
We also found that urea was reduced and platelets, CRP and ESR increased in PWME, although 
this was not significant in the multivariate analysis. An inverse relationship between platelets and 
CK was found in one study on rheumatoid arthritis, together with increases in inflammatory clinical 
markers such as ESR and CRP [25]. Platelets also tend to increase in inflammatory processes [38]. 
Nevertheless, the pattern of inflammatory markers in our study leads us to speculate that some 
degree of inflammation may be related to symptoms in people with mild/moderate ME/CFS. For 
people with severe disease, it seems that the inflammatory response may have been inhibited, either 
due to a lack of a persistent stimuli or to impairment of some aspects of the inflammatory response, 
which may indicate chronic disease with established complications. However, it is important to note 
that changes in inflammatory markers were relatively modest, and any further assumptions would 
need to be appropriately tested and confirmed in a further set of samples. We found lower levels of 
urea in mild/moderate cases, but not in those who were severely-affected. This could relate to 
creatinine levels, which were also lower in ME/CFS compared to controls; however, for creatinine, 
the lowest values were present in the most severely-affected. Abnormalities in the urea cycle have 
been reported in ME/CFS (e.g., [39,40]) 
Other findings including raised albumin and T4 are more difficult to explain. Raised albumin 
suggests malnutrition is not a main factor in ME/CFS in this study. The mildly raised T4 could suggest 
minor changes related to thyroid hormone metabolism, such as in its peripheral conversion, as 
previously suggested [41]. However, this hypothesis was not corroborated by other findings, which 
showed similar T3 and TSH levels between the groups, neither do our findings are typical of 
euthyroid sick syndrome. A higher prevalence of Gilbert’s syndrome in ME/CFS has been proposed 
in the past [42], but this was not found in this study, which showed similar bilirubin levels in cases 
and controls, with reduced bilirubin levels in people with severe ME/CFS compared to non-severe 
cases. 
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Further investigations with a larger sample size and more detailed explorations of metabolic 
pathways will be needed to confirm whether low CK activity is a primary or secondary event in 
ME/CFS or, indeed, whether it reflects some other metabolic dysfunction. This could benefit from the 
use of “diseased” controls groups, such as selected orthopaedic patients with prolonged immobility. 
Meanwhile, we suggest that CK could be used as a potential marker of severe ME/CFS. It is important 
to consider the clinical history and physical examination findings, as well as measures of activity 
(e.g., outputs from accelerometers) at the time of the blood draws for serum CK. Moreover, a “high-
normal” result in people who are often sedentary or bedbound, particularly those with severe 
ME/CFS, should be interpreted with caution, as it could indicate the presence of muscle injury. 
4.3. Study Strengths and Limitations 
The study investigated a group of people with well-characterised ME/CFS using robust 
standards of data and sample collection as described in the UK ME/CFS Biobank protocol [6]. In terms 
of ME/CFS research, this was a large sample: 272 PWME were tested, including 56 who were severely-
affected. However, the assessment of activity level was by self-report [6]. If this resulted in 
overestimation of activity levels in some groups, then differential misclassification may have resulted 
e.g., if the less active and the severely-affected ME/CFS cases may have overestimated their activity 
levels [43]. 
The inclusion of severely-affected ME/CFS participants, typically absent from most previous 
studies, may have been key to demonstrating abnormalities not previously reported. The results 
presented here come from routine laboratory tests in PWME and healthy controls. The purpose of 
the blood tests was primarily to exclude other diseases which could present with similar symptoms; 
the examination of muscle-related biochemical abnormalities was not in response to a specific 
hypothesis but was noted when all results were examined to test null hypotheses of no group 
differences between study groups in laboratory test findings. This means that we were not able to 
examine abnormalities in muscle/energy metabolism in more detail. However, our ability to 
investigate our findings further, e.g., through enhanced metabolomic studies and by accessing 
additional biobanked samples from the cohort, including at different time-points, will be 
instrumental in further understanding the changes reported here. 
5. Conclusions 
This is the first study to find significant lower concentrations of CK in PWME. Some indications 
of low CK values seem to have been overlooked previously when the trend towards lower values 
was discarded as not significant and was not investigated further. A single measurement of serum 
CK may not have enough sensitivity and specificity to be used as a biomarker for ME/CFS diagnosis, 
but, used alongside other clinical and laboratory markers, routine CK blood tests could not only help 
to diagnose ME/CFS accurately, but also to sub-group cases according to disease severity. It could 
potentially also be used as a prognostic marker, and as an outcome measurement for observational 
studies and clinical trials, as well as in clinical practice, pending further longitudinal studies 
examining the correlation of clinical and laboratory-based phenotypes over time. Whether people 
with severe ME/CFS featuring low CK constitute a unique sub-group of patients with distinct 
patterns of biochemical/pathophysiological abnormalities and symptoms, or whether they represent 
a different phase or an extreme spectrum of the disease, still needs to be clarified. 
Our findings give significant support to the growing body of evidence on metabolic 
abnormalities in ME/CFS, and we suggest further adequately-powered studies that include a fuller 
investigation of specific metabolic pathways to elucidate whether CK is a primary or secondary 
abnormality in all or in a sub-group of ME/CFS cases. Such studies should also help to elucidate the 
causes of such abnormalities. Correlating serum CK concentrations with objectively measured 
activity levels and other energy metabolism parameters could lead to a better understanding of the 
pathophysiological abnormalities involved in muscle use and recovery, and their relationship to 
symptoms such as post-exertional malaise and fatigue. 
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ROC curve receiver operating characteristic curve 
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Appendix A  
 
Figure A1. Histograms of serum creatine phosphokinase (CK) results from the UK ME/CFS Biobank 
participants, by category of recruitment. (a) Distribution of CK results (U/L); (b) Distribution of 
transformed lnCK. 
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Appendix B 
Table A1. Blood tests reference ranges used by NHS laboratories. 
Blood Tests Normal Ranges 1 
White blood count (WBC) (3.5–11.0) × 109/L 
Platelets (PLT) (140–400) × 109/L 
Haemoglobin 110–150 g/L 
Haematocrit 0.34–0.50 L/L 
Neutrophils (1.7–7.5) × 109/L 
Lymphocytes (1.0–4.0) × 109/L 
Monocytes (0.2–1.5) × 109/L 
Eosinophils (0.0–0.5) × 109/L 
Basophils (0.0–0.1) × 109/L 
Erythrocyte Sedimentation Rate (ESR) 0–20 mm/h 
Sodium 135–145 mmol/L 
Potassium 3.5–5.1 mmol/L 
Urea 2.1–7.1 mmol/L 
Creatinine 49–92 µmol/L 
Adjusted calcium 2.20–2.60 mmol/L 
Inorganic phosphate 0.80–1.45 mmol/L 
Total bilirubin <21 µmol/L 
Albumin 35–50 g/L 
Globulins 21–35 g/L 
Alkaline Phosphatase (ALP) <129 U/L 
Aspartate aminotransferase (AST) <31 U/L 
Total protein 63–82 g/L 
Creatine phosphokinase (CK) <320 U/L 
C Reactive protein (CRP) 0–5 mg/L 
Free T3 3.8–6.0 
Free T4 12.0–22.0 pmol/L 
Thyroid stimulant hormone (TSH) 0.30–4.20 mU/L 
Serum vitamin B12 160–925 ng/L 
Serum folate >2.9 µg/L 
Aldolase 1–7.5 U/L 
1 Normal reference ranges applied by the specific NHS laboratories, from the NHS collaboration 
hospitals, i.e. Royal Free Hospital and Norfolk and Norwich University Hospital in the UK. 
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